Menu Search
Equities

Matinas BioPharma Holdings Inc

MTNB:ASQ

Matinas BioPharma Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.746
  • Today's Change-0.154 / -17.11%
  • Shares traded448.19k
  • 1 Year change-93.00%
  • Beta1.7799
Data delayed at least 15 minutes, as of Nov 13 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Matinas BioPharma Holdings Inc's revenues fell -65.62% from 3.19m to 1.10m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 21.00m to a larger loss of 22.94m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-78.48%
Return on equity-97.59%
Return on investment-85.80%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Matinas BioPharma Holdings Inc fell by 2.04m. However, Cash Flow from Investing totalled 13.24m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 15.28m for operations while cash used for financing totalled 7.00k.
Cash flow per share-5.00
Price/Cash flow per share--
Book value per share3.81
Tangible book value per share2.94
More ▼

Balance sheet in USDView more

Matinas BioPharma Holdings Inc uses little debt in its capital structure as supported by a debt to capital ratio of 0.11%.
Current ratio6.39
Quick ratio--
Total debt/total equity0.001
Total debt/total capital0.001
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.